Lantheus Holdings (LNTH) Gains CMS Reimbursement Win Following A Fair Value Debate

Lantheus Holdings (LNTH) just picked up a fresh reimbursement win, with CMS granting Transitional Pass Through payment status and a permanent HCPCS code for its PYLARIFY TruVu PET imaging agent.

Lantheus Holdings’ latest reimbursement win comes after a powerful run, with the share price up 48.9% year to date and a 1-year total shareholder return of 87.1%. This comes even as the 90-day share price return declined 5.5% and shorter-term momentum cooled.

Spot similar reimbursement and product catalysts by scanning our hand-picked 34 healthcare AI stocks, which are also leaning into imaging and AI driven diagnostics.

Lantheus Holdings now trades near US$100 after a powerful run, while shorter term returns have cooled. Does that mix still leave enough upside in the risk reward to justify new money at today’s valuation?

Most Popular Narrative: 7% Undervalued

Lantheus Holdings is trading at $100.18 against a widely followed fair value estimate of $107.74, so the current quote sits below that narrative anchor while still close to the agreed Curium cash consideration of $102.50 per share.

The agreed acquisition of Lantheus Holdings by Curium for US$102.50 per share in cash plus up to US$12.00 per share in CVRs tied to commercial milestones through 2030 embeds expectations for future product execution, with the CVR structure directly linking potential incremental shareholder value to revenue and earnings delivery on the radiopharmaceutical portfolio.

See why 79 investors see Lantheus Holdings as 7% undervalued.

Result: Fair Value of $107.74 (UNDERVALUED)

Still, price pressure in PSMA PET imaging and the risk that Lantheus Holdings sees slower margin recovery if new agents stumble could quickly challenge that 7% undervalued story.

Find out about the key risks to this Lantheus Holdings narrative.

Next Steps

Feeling that mix of optimism and caution around Lantheus Holdings and its reimbursement momentum. Act quickly, check the underlying metrics yourself, and then weigh those 4 key rewards carefully.

Looking for more investment ideas beyond Lantheus Holdings?

You have seen how one reimbursement decision can reshape the story. Use that same lens to look for other opportunities before the crowd catches on.

• Target strong upside potential by scanning a focused list of quality candidates through 20 high quality undiscovered gems.
• Prioritise resilience by reviewing companies that pass tough balance sheet checks using the list of solid balance sheet and fundamentals (25 results).
• Consider steadier income streams by assessing higher yielding payers in the 8 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com